Cardiology

Your Article Summary

See Latest Articles

Update on the clinical use of the low-molecular-weight heparin, parnaparin
Vascular Health and Risk Management, 09/29/09

Camporese G et al. – Parnaparin is a low–molecular–weight heparin that has widely shown its efficacy and safety in prevention of venous thromboembolism, in the treatment of chronic venous disorders, and in the treatment of venous and arterial (stable and unstable angina, acute ST–segment elevation myocardial infarction) thrombosis. Parnaparin at the respective dosages of 3200, 4250, 6400, or 12800 IUaXa for a period ranging from 3 to 5 days to 6 months, is usually administered subcutaneously by means of once–daily regimen and is better tolerated than unfractionated heparin at the injection site. In the variety of commercially available low–molecular–weight heparins, parnaparin represents a useful therapeutic option, even though little evidence is available comparing the superiority or the equivalent efficacy and safety of parnaparin to that of the unfractionated heparin or placebo. This review summarizes the available literature on the use of parnaparin in different settings of cardiovascular diseases, including papers published during the past year and ongoing studies.

Today in Clinical Pharmacology...keeping you current

Receive free subspecialty "5-minute updates" via email

Rosiglitazone was non-inferior to metformin plus sulphonylurea for CV events but increased risk of HF and fractures in type 2 diabetes
Evidence-Based Medicine, 12/08/09

Review: aspirin reduces vascular events but increases bleeding in primary and secondary prevention
Evidence-Based Medicine, 12/08/09

In patients with type 2 diabetes, perindopril-indapamide had similar relative reductions in mortality and cardiac events regardless of AF status
Evidence-Based Medicine, 12/08/09

 See all of Clinical Pharmacology